UNSPSC 51152008: Dimethyltubocurarine or metocurine

This classification denotes a muscle relaxant with the molecular formula C40H48N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V0M92G2U26. As of Q4 2014, METOCURINE remains the US FDA Preferred Term for this commodity. Metocurine bears US NLM identifiers UMLS ID C0066465 and NCI Concept Code C76069. SMILES: C[N+]1(CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C6C(CC7=CC(=C(C=C7)OC)O3)[N+](CCC6=CC(=C5OC)OC)(C)C)OC)C.

UNSPSC 51152008 Dimethyltubocurarine or metocurine, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The two opportunities posted in the source window are unrelated: the Washington State Department of Corrections' RFQQK13020 solicits parenteral products, services, and equipment—including TPN and PPN solutions, intravenous fluids, and controlled substances for incarcerated individuals—while Seminole County, Florida's IFB60459723LAS procures naloxone and drug deactivation systems for community health. Neither opportunity targets dimethyltubocurarine or metocurine specifically. The Washington solicitation, posted September 8, 2026 with a response date of October 7, 2026, is the more substantial: it seeks multiple contractors across three regions of Washington correctional facilities, with contract terms running November 26, 2026 through June 30, 2030. The Seminole County opportunity (posted June 30, 2026, response due July 26, 2023—a date in the past relative to the current date of October 20, 2026) requests 1,900 units of naloxone and 800 drug deactivation systems annually on a fixed-fee basis with an initial two-year term and one-year renewal option.

The code shows little relevant recent activity. State and local procurement officers are not currently sourcing dimethyltubocurarine or metocurine under this UNSPSC designation, or if they are, those opportunities are not reflected in the recent posting record. The mismatch between the code's pharmaceutical specificity and the broader parenteral-products and harm-reduction equipment procurements posted suggests either misclassification by issuing bodies or dormant demand for this particular neuromuscular agent. Business development professionals evaluating this code should verify whether state and local health care or correctional systems in their target markets have independent procurement channels, standing contracts, or group purchasing arrangements for specialty anesthetics and neuromuscular blockers that bypass public bidding.